immunoglobulin heavy diversity 7-27Genealiases: []
Q-omics provides the consensus-scored IGHD7-27 profile across patient tissues and cancer cell-line models. IGHD7-27 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGHD7-27 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, IGHD7-27 RNA expression shows 6,668 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCEC, STAD, and COAD as cancer lineages where IGHD7-27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHD7-27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHD7-27 survival associations across molecular data types. IGHD7-27 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHD7-27 RNA expression–survival associations across cancer types. High IGHD7-27 expression shows unfavorable associations in UCEC, CHOL, STAD, TGCT, LUSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGHD7-27 RNA expression.
This table summarizes IGHD7-27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHD7-27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHD7-27 shows lower tumor expression in STAD. The STAD box plot shows higher IGHD7-27 RNA expression in normal versus tumor tissue (log2 FC = −2.890, t-test p < 0.001).
This table shows molecular features associated with IGHD7-27 in patient tissues and cancer cell lines. In patient samples, IGHD7-27 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
